NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to the QVC® Network With DERMAdoctor’s Eczema Balm
17 Novembre 2022 - 12:50PM
Business Wire
Duo package Calm Cool + Corrected Eczema +
Dermatitis Clinical Repair Balm to be featured on “Give Gorgeous -
Gifts With Purchase” on November 19 at 4 p.m. Eastern time
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company
developing and commercializing high-quality eyecare, skincare and
wound care products, announces that Chief Product Officer Audrey
Kunin, MD will return for her fourth appearance this year on the
QVC network. Dr. Kunin will discuss DERMAdoctor’s moisturizing Calm
Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical
Repair Balm on “Give Gorgeous – Gifts With Purchase” hosted by two
of QVC’s most popular hosts, Jennifer Coffey and Terri Conn, on
Saturday, November 19 at 4 p.m. Eastern time.
“I am excited to share our moisture-rich, problem-solving Calm
Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis Clinical
Repair Balm on QVC just in time for holiday giving,” said Dr.
Kunin. “Dry indoor air during the winter months can exacerbate
parched, eczema-prone skin, leading to itching, redness and
discomfort. Our nourishing balm maximizes hydration to calm
irritated skin with a special formulation of colloidal oatmeal
combined with time-honored, beloved dermatologic botanicals, and is
gentle enough to be used head to toe. Like all DERMAdoctor
products, it is formulated with a mixture of compassion and
expertise.”
Calm Cool + Corrected 1% Colloidal Oatmeal Eczema + Dermatitis
Clinical Repair Balm was recently selected as among the top 2022
picks for best eczema lotions by two medically reviewed online
publications: Medical News Today as the best full body lotion and
Verywell Health as the best calming lotion. Calm Cool + Corrected
1% Colloidal Oatmeal Eczema + Dermatitis Clinical Repair Balm
incorporates a special form of eczema-active 1% colloidal oatmeal
with enhanced beta glucan, an advanced complex of ceramides and
essential lipids, along with dermatologic botanicals including
evening primrose, black currant and borage seed oils and linoleic
acid.
Dr. Kunin is a board-certified dermatologist, author, clinician,
educator, television personality and recognized trailblazer in the
skincare industry. DERMAdoctor products are scientifically
formulated to provide measurable results for common skincare
concerns that have been overlooked by the beauty industry.
DERMAdoctor delivers on the promise that clinical skin therapy can
be simple and easy.
About Eczema
Eczema affects an estimated 31 million Americans, according to
the Asthma and Allergy Foundation of America. Atopic dermatitis,
the most common form of eczema, is a chronic, inflammatory skin
disease that results in widespread rashes and patches of itchy
skin. Those afflicted report limitations that impact their daily
activities and cause them to avoid social interactions.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically
created and clinically proven eyecare and skincare products.
NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash
Solution, is often prescribed by eyecare professionals for
blepharitis and dry-eye disease and is also available directly to
eyecare consumers through online distribution channels such as
Amazon. DERMAdoctor® offers more than 30 OTC
dermatologist-developed skincare products through the DERMAdoctor
website, well-known traditional and digital beauty retailers, and
international distributors. NovaBay also manufactures and sells
effective, yet gentle and non-irritating wound care products. The
PhaseOne® brand is distributed through commercial partners in the
U.S. for professional use only, and the NeutroPhase® brand is
distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in
this press release may be forward looking within the meaning of the
“safe harbor” provisions of the Private Securities Litigation
Reform Act of 1995, including statements about the commercial
progress and future financial performance of NovaBay
Pharmaceuticals, Inc. This release contains forward-looking
statements that are based upon management’s current expectations,
assumptions, estimates, projections and beliefs. These statements
include, but are not limited to, statements regarding our business
strategies, current product offerings, marketing efforts, and any
future revenue that may result from selling such products, as well
as generally the Company’s expected future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to the size of the potential
market for our products, the integration of DERMAdoctor’s business
into the Company’s business, the possibility that the available
market for the Company’s products will not be as large as expected,
the Company’s products will not be able to penetrate one or more
targeted markets, and revenues will not be sufficient to meet the
Company’s cash needs. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings and
Registration Statement on Form S-1 filing with the Securities and
Exchange Commission, especially under the heading “Risk Factors.”
The forward-looking statements in this release speak only as of
this date, and NovaBay disclaims any intent or obligation to revise
or update publicly any forward-looking statement except as required
by law.
Socialize and Stay Informed on
NovaBay’s Progress Like us on Facebook Follow us on
Twitter Connect with NovaBay on LinkedIn Visit NovaBay’s
Website
Avenova Purchasing
Information For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com Avenova.com
DERMAdoctor Purchasing
Information For DERMAdoctor purchasing information:
Please call 877-337-6237 or email service@dermadoctor.com
DERMAdoctor.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221117005116/en/
NovaBay Contact Justin Hall
Chief Executive Officer and General Counsel 510-899-8800
jhall@novabay.com
Investor Contact LHA
Investor Relations Jody Cain 310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024